A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 2, 2014, Pages 393-400

  Mao, Yicheng ^a,b   Wang, Jiang ^b   Zhao, Yuan ^b   Wu, Yun ^a   Kwak, Kwang Joo ^a   Chen, Ching Shih ^b   Byrd, John C ^b   Lee, Robert J ^a,b   Phelps, Mitch A ^b   Lee, L James ^a   Muthusamy, Natarajan ^b  

^a Ohio State University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

CD37; Drug delivery; FTY720; Leukemia; Liposome; Nanotechnology

Indexed keywords

CD37; DRUG DELIVERY; FTY720; LEUKEMIA; LIPOSOME; NANOTECHNOLOGY;

ANIMALS; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, NEOPLASM; APOPTOSIS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA; LIPOSOMES; MICE; MICE, INBRED ICR; NANOMEDICINE; PROPYLENE GLYCOLS; SPHINGOSINE; TETRASPANINS; WATER;

EID: 84895071225     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.08.001     Document Type: Article

References (43)

1. Strader C.R., Pearce C.J., Oberlies N.H. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod 2011, 74:900-907.
2. Suzuki S., Enosawa S., Kakefuda T., Shinomiya T., Amari M., Naoe S., et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996, 61:200-205.
3. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9:883-897.
4. Neviani P., Santhanam R., Oaks J.J., Eiring A.M., Notari M., Blaser B.W., et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007, 117:2408-2421.
5. Liu Q., Alinari L., Chen C.S., Yan F., Dalton J.T., Lapalombella R., et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010, 16:3182-3192.
6. Alinari L., Mahoney E., Patton J., Zhang X., Huynh L., Earl C.T., et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood 2011, 118:6893-6903.
7. Liao A., Broeg K., Fox T., Tan S.F., Watters R., Shah M.V., et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011, 118:2793-2800.
8. Matsuoka Y., Nagahara Y., Ikekita M., Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003, 138:1303-1312.
9. Skerjanec A., Tedesco H., Neumayer H.H., Cole E., Budde K., Hsu C.H., et al. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J Clin Pharmacol 2005, 45:1268-1278.
10. Braun W.E. Renal transplantation: basic concepts and evolution of therapy. J Clin Apher 2003, 18:141-152.
11. Egom E.E., Ke Y., Musa H., Mohamed T.M., Wang T., Cartwright E., et al. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 2010, 48:406-414.
12. Egom E.E., Mohamed T.M., Mamas M.A., Shi Y., Liu W., Chirico D., et al. Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol 2011, 301:H1487-H1495.
13. Meno-Tetang G.M., Li H., Mis S., Pyszczynski N., Heining P., Lowe P., et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 2006, 34:1480-1487.
14. Nagahara Y., Enosawa S., Ikekita M., Suzuki S., Shinomiya T. Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology 2000, 48:75-85.
15. Nagahara Y., Ikekita M., Shinomiya T. T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br J Pharmacol 2002, 137:953-962.
16. Daniel C., Sartory N., Zahn N., Geisslinger G., Radeke H.H., Stein J.M. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4(+)CD25(+) regulatory T cells. J Immunol 2007, 178:2458-2468.
17. Omar H.A., Chou C.C., Berman-Booty L.D., Ma Y., Hung J.H., Wang D., et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011, 53:1943-1958.
18. Liu Q., Zhao X., Frissora F., Ma Y., Santhanam R., Jarjoura D., et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008, 111:275-284.
19. David O.J., Kovarik J.M., Schmouder R.L. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet 2012, 51:15-28.
20. Kahan B.D., Karlix J.L., Ferguson R.M., Leichtman A.B., Mulgaonkar S., Gonwa T.A., et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003, 76:1079-1084.
21. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115:84-105.
22. Yu B., Mao Y., Yuan Y., Yue C., Wang X., Mo X., et al. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials 2013, 34:6185-6193.
23. Yu B., Mao Y., Bai L.Y., Herman S.E., Wang X., Ramanunni A., et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 2013, 121:136-147.
24. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
25. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995, 1239:133-144.
26. Chen J.L., Wang H., Gao J.Q., Chen H.L., Liang W.Q. Liposomes modified with polycation used for gene delivery: preparation, characterization and transfection in vitro. Int J Pharm 2007, 343:255-261.
27. Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 2001, 15:215-224.
28. Hung J.H., Lu Y.S., Wang Y.C., Ma Y.H., Wang D.S., Kulp S.K., et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 2008, 68:1204-1212.
29. Hertlein E., Triantafillou G., Sass E.J., Hessler J.D., Zhang X., Jarjoura D., et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010, 116:2554-2558.
30. Sze A., Erickson D., Ren L., Li D. Zeta-potential measurement using the Smoluchowski equation and the slope of the current-time relationship in electroosmotic flow. J Colloid Interface Sci 2003, 261:402-410.
31. Park J.W., Benz C.C., Martin F.J. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004, 31:196-205.
32. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
33. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8:1172-1181.
34. Awan F.T., Lapalombella R., Trotta R., Butchar J.P., Yu B., Benson D.M., et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010, 115:1204-1213.
35. Zhao X., Lapalombella R., Joshi T., Cheney C., Gowda A., Hayden-Ledbetter M.S., et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007, 110:2569-2577.
36. Lapalombella R., Yeh Y.Y., Wang L., Ramanunni A., Rafiq S., Jha S., et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012, 21:694-708.
37. Safra T., Muggia F., Jeffers S., Tsao-Wei D.D., Groshen S., Lyass O., et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2. Ann Oncol 2000, 11:1029-1033.
38. Park J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002, 4:95-99.
39. Yang X., Zhao X., Phelps M.A., Piao L., Rozewski D.M., Liu Q., et al. A novel liposomal formulation of flavopiridol. Int J Pharm 2009, 365:170-174.
40. Schweingruber N., Haine A., Tiede K., Karabinskaya A., van den Brandt J., Wust S., et al. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J Immunol 2011, 187:4310-4318.
41. Un K., Sakai-Kato K., Oshima Y., Kawanishi T., Okuda H. Intracellular trafficking mechanism, from intracellular uptake to extracellular efflux, for phospholipid/cholesterol liposomes. Biomaterials 2012, 33:8131-8141.
42. Mao Y., Triantafillou G., Hertlein E., Towns W., Stefanovski M., Mo X., et al. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clin Cancer Res 2013, 19:347-356.
43. Rafiq S., Cheney C., Mo X., Jarjoura D., Muthusamy N., Byrd J.C. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 2012, 26:1720-1722.